Phase I study of roniciclib (BAY1000394), an oral CDK inhibitor in Japanese patients with advanced solid tumors

被引：0
|
作者：
Seto, Takashi [1 ]
Nosaki, Kaname [1 ]
Shinoda, Gen [2 ]
Hashizume, Kensei [2 ]
Yamaguchi, Iku [2 ]
Tsuburaya, Jun [2 ]
Nogai, Hendrik [3 ]
Shitara, Kohei [4 ]
Yoh, Kiyotaka [4 ]
机构：
[1] Kyushu Natl Canc Ctr, Fukuoka, Japan
[2] Bayer Yakuhin Ltd, Osaka, Japan
[3] Bayer Pharma AG, Berlin, Germany
[4] Natl Canc Ctr Hosp East, Chiba, Japan
来源：
ANNALS OF ONCOLOGY | 2016年 / 27卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
O3-5-3
引用
收藏
页数：2
相关论文
共 50 条
  • [1] A phase I study with the oral pan-CDK inhibitor BAY 1000394 in patients with advanced stage small cell lung or ovarian cancer
    Bahleda, Rastilav
    Barlesi, Fabrice
    Audebert, Christine
    Perol, Maurice
    Ray-Coquard, Isabelle
    Strumberg, Dirk
    Schultheis, Beate
    Govindan, Ramaswamy
    Dy, Grace K.
    Zalcman, Gerard
    Walter, Annette O.
    Kornacker, Martin
    Ocker, Matthias
    Soria, Jean-Charles
    CANCER RESEARCH, 2014, 74 (19)
  • [2] Phase I study for ridaforolimus, an oral mTOR inhibitor, in Japanese patients with advanced solid tumors
    Yoshitaka Seki
    Noboru Yamamoto
    Yosuke Tamura
    Yasushi Goto
    Takashi Shibata
    Maki Tanioka
    Hajime Asahina
    Hiroshi Nokihara
    Yasuhide Yamada
    Takashi Shimamoto
    Kazuo Noguchi
    Tomohide Tamura
    Cancer Chemotherapy and Pharmacology, 2012, 69 : 1099 - 1105
  • [3] Phase I study for ridaforolimus, an oral mTOR inhibitor, in Japanese patients with advanced solid tumors
    Seki, Yoshitaka
    Yamamoto, Noboru
    Tamura, Yosuke
    Goto, Yasushi
    Shibata, Takashi
    Tanioka, Maki
    Asahina, Hajime
    Nokihara, Hiroshi
    Yamada, Yasuhide
    Shimamoto, Takashi
    Noguchi, Kazuo
    Tamura, Tomohide
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 69 (04) : 1099 - 1105
  • [4] A dose-escalation phase I study of oral pan-CDK inhibitor BAY 1000394 in patients with advanced solid tumors: Dose escalation with an intermittent 28 days on/14 days off schedule
    Grilley-Olson, Juneko E.
    Weiss, Glen J.
    Rajagopalan, Prabhu
    Henderson, David Andrew
    Kornacker, Martin
    Govindan, Ramaswamy
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [5] A first-in-human phase I study of oral pan-CDK inhibitor BAY 1000394 in patients with advanced solid tumors: Dose escalation with an intermittent 3 days on/4 days off schedule.
    Bahleda, Rastislav
    Gazzah, Anas
    Varga, Andrea
    Rajagopalan, Prabhu
    Henderson, David Andrew
    Kornacker, Martin
    Soria, Jean-Charles
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [6] A PHASE I STUDY OF RIDAFOROLIMUS, THE ORAL MTOR INHIBITOR, AS A SINGLE AGENT IN JAPANESE PATIENTS WITH ADVANCED SOLID TUMORS
    Seki, Y.
    Yamamoto, N.
    Goto, Y.
    Shibata, T.
    Tanioka, M.
    Nokihara, H.
    Yamada, Y.
    Azuma, H.
    Noguchi, K.
    Tamura, T.
    ANNALS OF ONCOLOGY, 2010, 21 : 174 - 174
  • [7] Phase I and pharmacokinetic study of sorafenib, an oral multikinase inhibitor, in Japanese patients with advanced refractory solid tumors
    Minami, Hironobu
    Kawada, Kenji
    Ebi, Hiromichi
    Kitagawa, Koichi
    Kim, Yon-il
    Araki, Kazuhiro
    Mukai, Hirofumi
    Tahara, Makoto
    Nakajima, Hikaru
    Nakajima, Keiko
    CANCER SCIENCE, 2008, 99 (07): : 1492 - 1498
  • [8] PHASE I STUDY OF RESMINOSTAT, AN ORAL HDAC INHIBITOR, IN JAPANESE PATIENTS WITH SOLID TUMORS
    Kitazono, Satoru
    Fujiwara, Yutaka
    Nakamichi, Shinji
    Mizugaki, Hidenori
    Nokihara, Hiroshi
    Yamamoto, Noboru
    Yamada, Yasuhide
    Tamura, Tomohide
    ANNALS OF ONCOLOGY, 2014, 25
  • [9] A phase I and pharmacokinetic study of taladegib, a Smoothened inhibitor, in Japanese patients with advanced solid tumors
    Hideki Ueno
    Shunsuke Kondo
    Shusuke Yoshikawa
    Koichi Inoue
    Valérie Andre
    Masaomi Tajimi
    Haruyasu Murakami
    Investigational New Drugs, 2018, 36 : 647 - 656
  • [10] A phase I and pharmacokinetic study of taladegib, a Smoothened inhibitor, in Japanese patients with advanced solid tumors
    Ueno, Hideki
    Kondo, Shunsuke
    Yoshikawa, Shusuke
    Inoue, Koichi
    Andre, Valerie
    Tajimi, Masaomi
    Murakami, Haruyasu
    INVESTIGATIONAL NEW DRUGS, 2018, 36 (04) : 647 - 656
12345